On November 21, Fortimedix Surgical announced that it had been successfully acquired by Medtronic. Fortimedix is known for its unique articulated instrument technology, which subverts tradition and is committed to setting a benchmark in the field of robotic and non-robotic endoscopic treatment and minimally invasive surgery. "We are delighted to announce that Fortimedix Surgical has officially joined the Medtronic family," the company shared on LinkedIn. "This collaboration will apply our articulated instrument technology to patient treatment and open a new chapter. We look forward to shining on the Medtronic platform."

The official website of Fortimedix shows that the company uses full laser cutting technology to create a multi-layer nested and welded product architecture. This innovative process magically transforms ordinary metal tubes into flexible articulated shafts, which have hundreds of precision moving parts after assembly, and are powerful and complex. This proprietary technology has shown great value in endoscopic treatment and minimally invasive surgery, and can achieve early endoscopic surgical intervention, that is, endocavity surgery, bringing good news to patients.

In 2015, the world's thinnest surgical solution was launched. In terms of featured products, Fortimedix Surgical announced that its FMX314 received the CE mark in 2016, and the product received FDA approval in 2015. It also said that the FMX314 is the world's thinnest single-port surgical solution and the world's first single-port surgical solution compatible with standard 15 mm trocars for minimally invasive laparoscopic surgery. The FMX314 addresses unmet needs in laparoscopic surgery by providing a small, simple and safe platform solution.

According to the company, because it is the first single-port platform compatible with standard 15 mm laparoscopic trocars, the FMX314 is expected to reduce port site complications, reduce postoperative pain, faster recovery and excellent cosmetic results compared to traditional multi-port laparoscopic surgery. The FMX314 simulates traditional multi-port laparoscopy, is easy to use, and enables surgeons to perform surgical steps ergonomically, thereby achieving a comfortable and safe single-port approach.

According to the official website, Fortimedix Surgical was founded in 2012 as an independent spin-off of the global leader in B2B contract stent manufacturing, serving leading medical device players in the cardiovascular field. Fortimedix's roots can be traced back to 1999, with a proven track record and 25 years of experience in product development and internal high-volume medical device manufacturing. Surgical is a fast-growing medical device company that aims to challenge the status quo of minimally invasive surgery by creating new devices with the advantages of single-port surgery.

The company is headquartered in Nus, the Netherlands, and has a US subsidiary in San Diego, California. As a global market leader in contract stent manufacturing, Fortimedix has a long history and has been a trusted partner in the medical device industry for 15 years. Fortimedix Surgical is committed to driving the development of minimally invasive surgery through intelligent innovation in surgical specialties to improve the quality of life of patients around the world.

Recently, Medtronic executives revealed their M&A strategy during the second quarter earnings call. When asked about the M&A strategy, Medtronic CEO Geoff Martha said Medtronic would adopt a "top-down" precision strategy and focus on small mergers and acquisitions. Although Geoff Martha did not disclose specific M&A targets, he and the interim CFO both emphasized the importance of small M&A and portfolio management. Martha said: "Small M&A is a key part of our growth blueprint. Our leadership team is reviewing priority areas from top to bottom, expecting them to become the focus of M&A." Medtronic not only focuses on high-growth markets and fields, but also aims to inject new vitality into mature businesses through small M&A.

Martha emphasized that portfolio management is a continuous optimization process, not a one-time task: "We always review the portfolio to ensure that it is in line with our mission and advantages to stand out in the fierce market competition." He further pointed out that the sophisticated layout of portfolio management will bring Medtronic steady, sustainable and innovation-driven mid-single-digit growth. Martha said: "This will directly increase our revenue and profitability, convert into profit leverage on the income statement, and then bring generous dividends and double-digit shareholder returns. Therefore, we are actively adjusting the portfolio to ensure that it continues to contribute to this goal." Looking ahead, Medtronic is more optimistic about its performance expectations for fiscal 2025. The company expects organic revenue growth to be between 4.75% and 5%, and non-GAAP diluted earnings per share to reach $5.44 to $5.50.

On November 19, Medtronic released its second quarter financial report for fiscal year 2025, reporting revenue of $8.4 billion, an increase of 5.3%, and organic growth of 5.0%. The company's CEO confidently pointed out that cutting-edge businesses such as TAVR, pulsed field ablation, neuromodulation, diabetes and renal denervation will continue to drive the company's prosperity. He also specifically revealed that the highly anticipated Hugo surgical robot will submit an application to the FDA in early 2025. The cardiovascular cardiovascular product portfolio includes cardiac arrhythmias and heart failure (CRHF), structural heart and aorta (SHA), and coronary and peripheral vascular (CPV) departments. Revenue was $3.102 billion, a reported increase of 6.1% and an organic increase of 5.6%, of which SHA grew by high single digits, CRHF and CPV grew by mid-single digits, all of which were organic growth.

Neuroscience The Neuroscience portfolio includes the Cranial and Spinal Cord Technologies (CST), Specialty Therapies, and Neuromodulation divisions. Revenue was $2.451 billion, up 7.1% as reported and 6.7% organically, with low double-digit growth in Neuromodulation and mid-single-digit growth in CST and Specialty Therapies, all organically. Medical Surgery The Medical Surgery portfolio includes the Surgery and Endoscopy (SE) division and the Acute Care and Monitoring (ACM) division. Revenue increased 1.2% to $2.128 billion as reported and 0.7% organically, with low single-digit organic growth in ACM and flat organic growth in SE. SE year-over-year performance was impacted by a difficult comparison to the prior year's surgical supply recovery, with high single-digit sequential growth. Diabetes revenue was $686 million, up 12.4% year-over-year, with 11.0% organic growth.

The acquisition of Endoscopy and Minimally Invasive Therapies is highly complementary and synergistic with Medtronic's previous business layout. In the field of endoscopy, on December 23, 2020, Xinguangwei Medical signed a strategic cooperation agreement with Medtronic (Shanghai) Management Co., Ltd. The two parties jointly planned comprehensive cooperation in the fields of endoscopy innovative product development, academic activities, education and training, commercial promotion, sales services, etc. In 2021, Xinguangwei Medical announced that it had obtained nearly 400 million yuan in Series A financing, led by Hillhouse Capital and Lilly Asia Fund, and jointly assisted in this financing by Jingwei China, Medtronic, Chengcheng Chuangban, and Weihao Chuangxin Investment.

In the field of laparoscopic surgical robots, in October 2021, Medtronic's Hugo RAS system obtained the EU CE certification. In October 2023, at the 6th CIIE, Medtronic stated that the Hugo RAS robot-assisted surgical system has established a training center in Taiwan, China. On May 24, 2024, Medtronic announced the launch of more clinical studies of its Hugo robot-assisted surgical system to expand its indications to hernia repair and gynecology. Medtronic's Hugo soft tissue surgical robot has made significant commercial progress in Europe, Latin America, Asia and other regions, and is expected to challenge the market position of the da Vinci surgical robot globally in the future.

https://mp.weixin.qq.com/